Research programme: protease activated cancer therapy - Dendreon
Alternative Names: CVS 10290; PACT; Research programme: protease activated cancer therapy - CorvasLatest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Dendreon Corporation
- Class
- Mechanism of Action Protease stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Jan 2004 The activities of Dendreon San Diego LLC are being relocated to Dendreon's Seattle headquarters
- 04 Aug 2003 Corvas International has been acquired by Dendreon Corporation and is now called Dendreon San Diego LLC
- 22 Jul 2003 Data presented at the 94th Annual Meeting of the American Association for Cancer Research (AACR-2003) have been added to the Cancer pharmacodynamics section